DxS Ltd.
DxS is a personalized medicine company that meets the needs of the pharmaceutical industry for biomarkers and companion diagnostics to support the development and sales of cancer and other therapies. The company provides both biomarker products, which are used predominately during clinical trials, and companion diagnostics, which aid doctors in selecting therapies for patients. Working in partnership with drug companies, DxS offer validated biomarker assays to support drug development and then regulatory approval, by identifying likely responders to drug therapies. DxS have launched the world's first cancer mutation companion diagnostic to support Amgen's Vectibix colorectal cancer therapy. DxS kits detect mutations in oncogenes associated with cancer drug response. TheraScreen is the range of CE-marked diagnostic products for detecting mutations in the EGFR and K-RAS genes. Validated biomarker kits are available for research use for EGFR, RAS, RAF, BCR-ABL and other genes that show a correlation between patient mutation status and drug response.
Cross
Joanne
J
DxS Ltd, 48 Grafton Street, Manchester, M13 9XX, UK. Joanne.cross@dxsdiagnostics.com
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D015195:Drug Design; D004345:Drug Industry / Q000379:methods / Q000639:trends*; D006801:Humans; D011237:Predictive Value of Tests; D011933:Reagent Kits, Diagnostic / Q000639:trends*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011933:Reagent Kits, Diagnostic